14-07-2010: BRAIN AG has acquired a minority share in Enzymicals AG. This biotechnology company was founded in 2009 as a spin-off by a management team from the workgroup led by Prof. Dr. Uwe Bornscheuer from Ernst-Moritz-Arndt University Greifswald with support from the EXISTProgramme of the Federal Ministry for Economy and Technology (BMWi). The strategic investment of BRAIN AG in the Greifswald based company that specializes in biocatalytic production of fine and special chemicals as well as enzyme production enhances the previous activities of both companies in the biocatalysis sector.
The company from Greifswald focusses on producing and selling fine and specialty chemicals as well as the
relevant biocatalysts and process development. BRAIN has now acquired a minority share in Enzymicals in order to form a strategic alliance, which brings together complementary modules of the value chain for biocatalytic production of fine and specialty chemicals. This step follows a long tradition of successful collaboration between BRAIN and the cofounder of Enzymicals AG, Prof. Dr. Uwe Bornscheuer and provides a
broader commercial platform for this collaboration.
“We see our strategic commitment to Enzymicals as a further step towards establishing white biotechnology as a future technology in Europe, forging the way towards biologizing key industries and the sustainable optimization of industrial processes”, explains Dr. Jürgen Eck, CTO of BRAIN AG. “For many years BRAIN has been successfully cooperating with Prof. Dr. Bornscheuer and his team in the field of biocatalysis. This has already generated many innovative products among various enzyme categories such as esterases, laccases and monooxygenases. Our objective is to continue and intensify these activities with Enzymicals AG.”
As the industrial coordinator of the innovation alliance, the biotechnology company BRAIN AG has announced that the Natural Life Excellence Network 2020 (NatLifE 2020) innovation alliance is the first alliance to receive the official approval letter under the “Industrial Biotechnology Innov ... more
BRAIN AG has announced the expansion of its IP portfolio to include the MMPI (matrix metalloproteinase inhibitor) peptide. Now owned by BRAIN, the recombinant human bioactive molecule will be manufactured by BRAIN as a proprietary bioactive compound going forward and exclusively used in cos ... more
The supervisory board and the board of management of the biotechnology company BRAIN AG agreed on a €60m capital increase during a meeting of the supervisory board held on 19 November 2012. The capital increase helps pave the way for the implementation of BRAIN’s “buy-and-build” industriali ... more
BRAIN AG is an industrial “white” biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to th ... more
"We are happy to establish processes from development via production to market entry together with Herbrand PharmaChemicals" states Dr. Menyes from Enzymicals AG while visiting the running production sites of Herbrand PharmaChemicals GmbH, where soon biocatalytic processes for the productio ... more
The Enzymicals AG gained proprietary rights for the well-known recombinant pig liver esterases (PLE) from Evonik AG in Hanau. The intellectual property (IP) covers a range of PLE isoenzymes for hydrolysis of several compounds such as esters of secondary and tertiary alcohols, lactones and c ... more
BRAIN AG has acquired a minority share in Enzymicals AG. This biotechnology company was founded in 2009 as a spin-off by a management team from the workgroup led by Prof. Dr. Uwe Bornscheuer from Ernst-Moritz-Arndt University Greifswald with support from the EXISTProgramme of the Federal Mi ... more
The focus of Enzymicals is the development, production and utilisation of innovative biocatalysts. We cover the entire value chain from biocatalyst discovery via their optimisation by protein engineering tools to the efficient application in biocatalysis. This includes the development of ec ... more